Related Experiment Video
Updated: Aug 6, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease
1Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Alzheimer's Disease Center, and Center on Aging, University of California, Los Angeles, Los Angeles, CA, USA. gsmall@mednet.ucla.edu
Abstract:
Structural neuroimaging is a routine component of the diagnostic evaluation of dementia that is used to rule out potential causes of mental impairment, whereas functional imaging can differentiate different forms of dementia. Neuroimaging also offers promise as a surrogate marker for clinical trials, and new technologies have been developed to provide measures of amyloid plaques and neurofibrillary tangles, the neuropathological hallmarks of Alzheimer's disease. Combining imaging with genetic risk data will likely improve diagnostic accuracy. These new findings warrant reconsideration of current guidelines on the use of neuroimaging in diagnosis and research in dementia.
Related Concept Videos
Dementia l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
Alzheimer Disease ll: Pathophysiology
